US GAO says FDA failed to address some risks in heparin crisis response
This article was originally published in SRA
Executive Summary
In response to the 2008 heparin crisis, the US Food and Drug Administration increased its activities related to oversight of heparin firms but did not address risks related to working with external entities that had ties to those firms, says a new report by the Government Accountability Office1.
You may also be interested in...
Global medtech alliance approves six new member associations
An emerging alliance of medical technology industry associations representing innovative companies that currently develop and manufacture 85% of the world's medical devices, diagnostics and equipment has approved the membership applications of six more associations, bringing the total number of members to 19.
Global medtech alliance approves six new member associations
An emerging alliance of medical technology industry associations representing innovative companies that currently develop and manufacture 85% of the world's medical devices, diagnostics and equipment has approved the membership applications of six more associations, bringing the total number of members to 19.
US FDA scrutiny of DTC genetic tests continues
The US FDA's devices unit has written to three genetic testing companies warning them that they may be marketing their products and services without clearance by the agency.